Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amyris Inc    AMRS

AMYRIS INC (AMRS)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

AMYRIS : Cosan and Amyris Forming Novvi S.A. for Global Production and Commercialization of Renewable Base Oils

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2011 | 02:15pm CEST

Cosan S.A. Industria e Comércio (BM&FBovespa:CSAN3) and Amyris, Inc. (NASDAQ:AMRS) announced today that they have executed a Joint Venture Implementation Agreement as the final step toward the commencement of operations in Novvi S.A., the Brazilian company established for the worldwide development, production and commercialization of renewable base oils made from Biofene®, Amyris's renewable farnesene. The companies executed in December 2010 an agreement to set the preliminary terms and the general conditions to conduct a set of business, technical and commercial studies and tests with the goal to assess the feasibility of the formation and implementation of a Joint Venture. The parties have now completed feasibility studies and are establishing the operating joint venture entity.

Novvi plans to commercialize a line of synthetic, renewable base oils for the lubricants market. Novvi's base oils are designed to improve upon key environmental metrics including biodegradability, toxicity and renewability when compared with petroleum-sourced base oils, while delivering performance characteristics comparable to Group III and Group IV base oils. Novvi expects to source Biofene initially from Amyris production facilities, convert it through chemical processing into high-end renewable base oils and market and distribute these base oils worldwide. Longer term, Novvi may construct dedicated Biofene production facilities.

"The formation of Novvi provides another important channel for commercialization of Biofene, and we are pleased to have Cosan as our partner in this," said Paulo Diniz, chief executive officer of Amyris Brasil. "We expect Novvi to introduce its first products starting next year."

"We have completed the market studies and production capabilities assessment and are now ready to operate our joint venture with Amyris," said Nelson Gomes, head of Cosan Lubricants. "The combination of Amyris's Biofene infrastructure and technology platform with our feedstock capabilities and supply and distribution infrastructure creates the foundation for Novvi to become the leader in high-performance renewable synthetic base oils."

About Amyris

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules - flexible building blocks which can be used in a wide range of products. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil S.A., a wholly owned subsidiary, has over 100 employees based in Campinas, Brazil and oversees Amyris's production and commercialization in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels, LLC. More information about Amyris is available at www.amyris.com.

About Cosan

Cosan is a fully integrated energy company. Raízen, its joint venture with Shell, is the world's largest producer of sugar and ethanol from sugarcane, with crushing capacity of 65 million tons of sugarcane, and the third largest fuel distributor in Brazil. Cosan is also the third largest Brazilian lubricants manufacturer and is present in the sugar logistics for the retail market with the União brand and for exports through its subsidiary Rumo.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as statements regarding production, commercialization and anticipated benefits of our products) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production or commercialization of products, our reliance on third parties to achieve our goals, and other risks detailed in the "Risk Factors" section of Amyris's annual report on Form 10-K filed on March 14, 2011 and on Form 10-Q filed May 11, 2011. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris and Biofene are trademarks or registered trademarks of Amyris, Inc.

Amyris, Inc.
Schwartz Communications
Merrill Freund or Alison Mickey, 415-817-2557
[email protected]
or
Cosan
Máquina Public Relations, 11 3147-7391
11 3147-7439
[email protected]


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMYRIS INC
06/15AMYRIS : Biossance – Save the Fishes… And Your Skin.
PU
06/15AMYRIS : Announces Signing of Major UCP in Porto/AICEP Consortium Project Agreem..
AQ
06/14AMYRIS : Leads the Way
PU
06/14AMYRIS : Set to Join Russell Microcap Index
AQ
06/12Amyris Announces Signing of Major UCP in Porto/AICEP Consortium Project Agree..
GL
06/12AMYRIS : Set to Join Russell Microcap Index
AQ
06/11AMYRIS : Biossance – Cocktails, Anyone?
PU
06/11AMYRIS : Set to Join Russell Microcap® Index
AQ
06/05AMYRIS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
05/23AMYRIS, INC. : Change in Directors or Principal Officers, Submission of Matters ..
AQ
More news
News from SeekingAlpha
2017Amyris (AMRS) Investor Presentation - Slideshow 
2017Amyris' (AMRS) CEO John Melo on Q1 2017 Results - Earnings Call Transcript 
2017Amyris misses by $0.04, misses on revenue 
2017Notable earnings after Monday?s close 
2017INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Apollo Global, Pulse Biosciences, Acacia .. 
Financials ($)
Sales 2018 188 M
EBIT 2018 -10,6 M
Net income 2018 -98,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 27,95
Capi. / Sales 2018 1,49x
Capi. / Sales 2019 1,01x
Capitalization 280 M
Chart AMYRIS INC
Duration : Period :
Amyris Inc Technical Analysis Chart | AMRS | US03236M1018 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 12,5 $
Spread / Average Target 124%
EPS Revisions
Managers
NameTitle
John G. Melo President, Chief Executive Officer & Director
Geoffrey Mark Duyk Chairman
Eduardo Alvarez Chief Operating Officer
Kathleen Valiasek Chief Financial Officer
Joel Cherry President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
AMYRIS INC-67.12%280
HENKEL-2.13%51 382
ECOLAB3.50%40 067
SIKA AG0.00%20 823
SYMRISE5.22%11 400
JOHNSON MATTHEY PLC20.00%9 472